Sun Pharmaceutical Industries is currently trading at Rs. 532.50, up by 4.00 points or 0.76% from its previous closing of Rs. 528.50 on the BSE.
The scrip opened at Rs. 536.35 and has touched a high and low of Rs. 537.70 and Rs. 530.30 respectively. So far 195543 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 540.75 on 31-Jul-2020 and a 52 week low of Rs. 315.20 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 540.75 and Rs. 487.65 respectively. The current market cap of the company is Rs. 128004.52 crore.
The promoters holding in the company stood at 54.69%, while Institutions and Non-Institutions held 32.81% and 12.50% respectively.
Sun Pharmaceutical Industries has launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.
The company will work closely with the government and medical community to ensure availability of FluGuard to patients across the country. The stocks of FluGuard will be available in the market from this week.
Sun Pharma is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.